--- title: "ERAS 投資者警報：Kirby McInerney LLP 正在調查涉及 Erasca, Inc.的潛在索賠" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/286975698.md" description: "Kirby McInerney LLP 正在調查針對 Erasca, Inc.（納斯達克代碼：ERAS）的潛在索賠，涉及在 Revolution Medicines 提出的專利侵權指控後可能違反聯邦證券法的情況。這一消息導致 Erasca 的股票下跌了約 48%。目前尚未提起訴訟，調查仍在進行中。擁有信息或感興趣的投資者被鼓勵與該律師事務所聯繫" datetime: "2026-05-19T23:12:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286975698.md) - [en](https://longbridge.com/en/news/286975698.md) - [zh-HK](https://longbridge.com/zh-HK/news/286975698.md) --- # ERAS 投資者警報：Kirby McInerney LLP 正在調查涉及 Erasca, Inc.的潛在索賠 **ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.** The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. \[LEARN MORE ABOUT THE INVESTIGATION\] **What Happened?** On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026. **What Should I Do?** At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. \[LEARN MORE ABOUT SECURITIES CLASS ACTIONS\] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Kirby McInerney LLP Lauren Molinaro, Esq. 212-699-1171 https://www.kmllp.com https://securitiesleadplaintiff.com/ investigations@kmllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260519928781/en/ ### 相關股票 - [ERAS.US](https://longbridge.com/zh-HK/quote/ERAS.US.md) - [RVMD.US](https://longbridge.com/zh-HK/quote/RVMD.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [RVMDW.US](https://longbridge.com/zh-HK/quote/RVMDW.US.md) ## 相關資訊與研究 - [Erasca 在美國銀行會議上展示了令人矚目的 ERAS-0015 肺癌數據，並討論了 FDA 審批路徑](https://longbridge.com/zh-HK/news/286652404.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2% 需考慮加息](https://longbridge.com/zh-HK/news/287171073.md) - [“搞錢”，才是 Revolution 千億神話密碼](https://longbridge.com/zh-HK/news/286888792.md)